Recce Pharmaceuticals — Up to A$85m of overseas R&D funding secured
Recce Pharmaceuticals recently reported that the Australian government has agreed to provide it with up to A$85m in future cash rebates over the...
128 Views
Recce Pharmaceuticals — Phase III Indonesian DFI trial underway
Recce has reached a key milestone with the start of patient dosing in its Phase III Indonesian-focused study of the topical gel formulation (R327G)...
213 Views
Recce Pharmaceuticals — Funding secured to start Phase III pivotal trials
Recce is raising up to A$15.8m in equity fundraising through a now-completed A$5.0m share placement and an entitlement offer for remaining...
266 Views
Recce Pharmaceuticals — Gearing up for an eventful year for R327G
Recce is preparing to start a registrational Indonesian Phase III study of the topical gel formulation (R327G) of its lead anti-infective...
554 Views
Recce Pharmaceuticals — Positive R327G Phase II ABSSSI study results
Recce has reported positive results from its open-label Phase II study assessing RECCE® 327 topical gel (R327G) in patients with acute bacterial...
159 Views